glp·helper
glphelper.com/mounjaro/wisconsin/madison
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Madison, WI

Verified Mounjaro providers in Madison, WI. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Mounjaro weight loss →trial-anchored estimate
city providers
38
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Wisconsin
38 of 38 shown

Find a Mounjaro provider in Wisconsin.

Every entry is checked against the NPI registry and the Wisconsin medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Wisconsin city · /mounjaro/wisconsin/{city}
§ 03Getting Mounjaro in Madison
38 providers · Madison, WI

How to get Mounjaro in Madison.

38 GLP-1 prescribers and 7 local resource types are on record for Madison, plus 2 nearby towns in the directory.

Prescribers in Madison
38 prescribers
38 GLP-1 prescribers in Madison, most listed as Family Medicine (15), Internal Medicine, Endocrinology, Diabetes & Metabolism (14) and Internal Medicine (8). Any Wisconsin-licensed physician, nurse practitioner, or PA can prescribe Mounjaro, over video or in person. The nearest towns on record are Milwaukee (31 providers) and Green Bay (31 providers).
Around the prescription in Madison
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Madison.
Medicaid (weight loss)
Covered
As of April 2026, Wisconsin Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Wisconsin’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Wisconsin

Diagnosed diabetes reaches 9.6% of adults in Wisconsin.

of Wisconsin adults have obesity
37.4%
diagnosed diabetes
9.6%

Age-adjusted estimates for Wisconsin, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight losswhat happens after GLP-1s stop
§ 05Support around Mounjaro in Madison
6 fitness clubs

The prescription is one part. Here is the rest, in Madison.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Madison, WI, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Warner Park Community Recreation Center
REC CENTER
4.6 on Google · 197 reviews
1625 Northport Dr
Website
Bakke Recreation & Wellbeing Center
REC CENTER
4.6 on Google · 179 reviews
1976 Observatory Dr
Website
Nicholas Recreation Center
REC CENTER
4.5 on Google · 161 reviews
797 W Dayton St
Website
CrossFit Mojo
FITNESS
5.0 on Google · 138 reviews
6111 Cottonwood Dr
Website
Allegro Fitness: CrossFit + Hyrox (formerly CrossFit Big Dane)
FITNESS
4.9 on Google · 131 reviews
813 Post Rd
Website
Carbon World Health
FITNESS
4.8 on Google · 78 reviews
340 S Whitney Way #100
Website

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Tanya Hansen, RN BSN
NUTRITIONIST
Nutritionist · Education
20 S Park St
Call 608-287-2770NPI 1598732679
Marian Holton-Manuel, Nutritionist
NUTRITIONIST
Nutritionist
6401 Dylyn Dr
Call 608-335-4496NPI 1578294096
Apiramy Jeevananthan, RD
NUTRITIONIST
Nutritionist
2202 S Park St
Call 608-443-5480NPI 1548980840
Jill Lamers
NUTRITIONIST
Nutritionist · Education
4849 Sheboygan Ave Apt 111
Call 608-658-2976NPI 1609573260
Michelle Pagoaga, RN
NUTRITIONIST
Nutritionist · Education
20 S Park St
Call 608-287-2770NPI 1851352215
Deborah Roussos, RD
NUTRITIONIST
Nutritionist
1265 John Q Hammons Dr
Call 608-251-4156NPI 1720171549
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Mounjaro cash price (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Mounjaro providers in Wisconsin

NPI-verified Mounjaro (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Mounjaro in other states

Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in Wisconsin

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]